Positive Phase 2 Results for Abdakibart Propel Avalo Therapeutics to Phase 3
AVTX has more than doubled off its 52-week low of $3.39.
Summary
Avalo Therapeutics announced highly positive topline results from its Phase 2 LOTUS trial for abdakibart, a significant de-risking event for the company's pipeline. The trial successfully met its primary HiSCR75 endpoint at both tested doses, demonstrating statistically significant improvement over placebo, alongside favorable safety data. This strong performance validates the drug's potential and is a critical step towards commercialization for the biotech firm. The company plans to advance abdakibart into a registrational Phase 3 program, which will be the next major catalyst. Investors will now focus on the details of the Phase 3 trial design and timelines, as well as the full data presentation at an upcoming medical congress.
At the time of this announcement, AVTX was trading at $16.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.4M. The 52-week trading range was $3.39 to $20.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.